We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
51
DELISTED
Immunogen Inc
IMGN
$8.95M 0.07%
+999,496
New +$7.24M
OSIR
52
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$8.78M 0.07%
499,193
-11,413
-2% -$192K
PRQR icon
53
ProQR Therapeutics
PRQR
$246M
$8.75M 0.07%
400,000
– –
ARWR icon
54
Arrowhead Research
ARWR
$12.1B
$8.73M 0.07%
1,290,187
+59,385
+5% +$421K
VIRX
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.84M 0.07%
15,238
– –
LJPC
56
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.54M 0.06%
412,008
-9,623
-2% -$195K
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.51M 0.06%
495,908
-9,510
-2% -$133K
EIGR
58
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.95M 0.06%
815
-18
-2% -$157K
KPTI icon
59
Karyopharm Therapeutics
KPTI
$155M
$6.64M 0.06%
14,466
+8,193
+131% +$3.53M
JUNO
60
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.07M 0.05%
100,000
– –
FMI
61
DELISTED
Foundation Medicine, Inc.
FMI
$5.98M 0.05%
124,255
-1,892
-1% -$85.8K
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
$5.68M 0.05%
571,000
– –
LGND icon
63
Ligand Pharmaceuticals
LGND
$5.78B
$5.66M 0.05%
117,638
-22
-0% -$843
TTHI
64
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$5.25M 0.04%
+769,230
New +$5.31M
AMRN
65
Amarin Corp
AMRN
$297M
$5.16M 0.04%
+110,286
New +$3.37M
STML
66
DELISTED
Stemline Therapeutics, Inc.
STML
$4.83M 0.04%
333,497
-5,174
-2% -$79.2K
CYTR
67
DELISTED
CytRx Corp
CYTR
$4.45M 0.04%
219,998
-5,002
-2% -$93.1K
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$4.37M 0.04%
232,481
+30,518
+15% +$630K
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$4.34M 0.04%
115,216
-57,198
-33% -$2.27M
INFI
70
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.26M 0.04%
305,037
-6,988
-2% -$107K
WINT
71
DELISTED
Windtree Therapeutics Inc
WINT
$4.25M 0.04%
254,975
-5,891
-2% -$116K
RCPT
72
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$3.94M 0.03%
23,900
– –
SAGE
73
DELISTED
Sage Therapeutics
SAGE
$3.77M 0.03%
75,000
– –
LRMR icon
74
Larimar Therapeutics
LRMR
$376M
$3.75M 0.03%
+7,895
New +$3.75M
IONS icon
75
Ionis Pharmaceuticals
IONS
$8.93B
$3.64M 0.03%
57,140
-39,163
-41% -$2.66M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.